TOKYO, Jun 25 (Pulse News Wire) – StemCell Institute (7096.T) disclosed that its parent company, Nippon Trim Co., Ltd., holds a controlling stake of 71.3%. As of March 31, 2026, Nippon Trim owns 71.3% of the voting rights directly without any additional aggregated holdings.
Nippon Trim Group includes seven consolidated subsidiaries and four associated companies, primarily engaged in electrolyzed hydrogen water production and sales. In contrast, StemCell Institute focuses on cell banking and regenerative medical services, operating independently from Nippon Trim’s core businesses.
The institute makes independent decisions on operational policies and strategic directions without prior approval from the parent company. On June 23, 2026, StemCell Institute’s President Shizawa Takafumi was appointed as a non-executive director of Nippon Trim during their annual shareholders' meeting.
Despite some personal connections, StemCell Institute maintains strong operational independence due to distinct business areas and decision-making processes.
🟢 Confidence: High AI-translated content.